This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Source: OpenUrlAbstract/FREE Full Text
Investigators from multiple institutions conducted a retrospective study to assess the risk of malignancy in children with juvenile idiopathic arthritis (JIA), inflammatory bowel disease (IBD), or plaque psoriasis (PsO) treated with tumor necrosis factor inhibitors (TNFi). For the study, the investigators abstracted data from a national US Medicaid database during the period 2000–2010, and from the Truven MarketScan files, which include US national claims data from employer-provided commercial insurance between 2010 and 2014. Diagnostic codes were used to identify children >6 months and <18 years old with JIA, IBD, or PsO, and prescription claim data were reviewed to determine if study children received a TNFi (including adalimumab, certolizumab, etanercept, golimumab, and infliximab). Available demographic data were also abstracted from the databases. Malignancies in study …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.